The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Xia, Bing ^a   Chen, Gui Yuan ^a   Cai, Xu Wei ^a   Zhao, Jian Dong ^a   Yang, Huan Jun ^a   Fan, Min ^a   Zhao, Kuai Le ^a   Fu, Xiao Long ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; PLATINUM;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION RESPONSE; CHINA; DISEASE FREE SURVIVAL; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE FRACTIONATION; RADIOMETRY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHINA; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; RADIATION DOSAGE; RADIOMETRY; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 79955990117     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-50     Document Type: Article

References (33)

1. De Ruysscher D, Vansteenkiste J. Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects. Radiother Oncol 2000, 55:1-9.
2. Murray N, Turrisi AT. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol 2006, 1:270-278.
3. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265-271. 10.1056/NEJM199901283400403, 9920950.
4. Miller KL, Marks LB, Sibley GS, Clough RW, Garst JL, Crawford J, Shafman TD. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003, 56:355-359. 10.1016/S0360-3016(02)04493-0, 12738309.
5. Roof KS, Fidias P, Lynch TJ, Choi NC. Radiation dose escalation in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003, 57:701-708. 10.1016/S0360-3016(03)00715-6, 14529774.
6. Bogart JA, Herndon JE, Lyss AP, Watson D, Miller AA, Lee ME, Turrisi AT, Green MR. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 2004, 59:460-468. 10.1016/j.ijrobp.2003.10.021, 15145163.
7. Miller AA, Wang XF, Bogart JA, Hodgson LD, Rocha Lima CM, Radford JE, Vokes EE, Green MR. Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J Thorac Oncol 2007, 2:645-651. 10.1097/JTO.0b013e318074bbf5, 17607121.
8. Komaki R, Swann RS, Ettinger DS, Glisson BS, Sandler AB, Movsas B, Suh J, Byhardt RW. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 2005, 62:342-350. 10.1016/j.ijrobp.2004.11.030, 15890573.
9. Komaki R, Paulus R, Ettinger DS, Videtic GM, Bradley JD, Glisson BS, Choy H. A phase II study of accelerated high-dose thoracic radiation therapy (AHTRT) with concurrent chemotherapy for limited small cell lung cancer: RTOG 0239[abstract]. J Clin Oncol 2009, 27:s388.
10. Tada T, Minakuchi K, Koda M, Masuda N, Matsui K, Kawase I, Nakajima T, Nishioka M, Fukuoka M, Kozuka T. Limited-stage small cell lung cancer: local failure after chemotherapy and radiation therapy. Radiology 1998, 208:511-515.
11. Choi NC, Carey RW. Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma: an update. Int J Radiat Oncol Biol Phys 1989, 17:307-310. 10.1016/0360-3016(89)90444-6, 2546906.
12. Coy P, Hodson I, Payne DG, Evans WK, Feld R, MacDonald AS, Osoba D, Pater JL. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian Multicenter Randomized Trial. Int J Radiat Oncol Biol Phys 1988, 14:219-226. 10.1016/0360-3016(88)90424-5, 2828289.
13. Chen GY, Jiang GL, Wang LJ, Qian H, Fu XL, Yang H, Wu KL, Zhao S. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial. Int J Radiat Oncol Biol Phys 2005, 61:70-75. 10.1016/j.ijrobp.2004.04.058, 15629596.
14. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989, 62:679-694. 10.1259/0007-1285-62-740-679, 2670032.
15. Bepler G, Jaques G, Neumann K, Aumüller G, Gropp C, Havemann K. Establishment, growth properties, and morphological characteristics of permanent human small cell lung cancer cell lines. J Cancer Res Clin Oncol 1987, 113:31-40. 10.1007/BF00389964, 3029138.
16. NCCN guidelines for small-cell lung cancer. , http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
17. Tomita N, Kodaira T, Hida T, Tachibana H, Nakamura T, Nakahara R, Inokuchi H. The impact of radiation dose and fractionation on outcomes for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010, 76:1121-1126. 10.1016/j.ijrobp.2009.03.069, 19665321.
18. Schild SE, Bonner JA, Hillman S, Kozelsky TF, Vigliotti AP, Marks RS, Graham DL, Soori GS, Kugler JW, Tenglin RC, Wender DB, Adjei A. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol 2007, 25:3124-3129. 10.1200/JCO.2006.09.9606, 17634491.
19. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003, 362:933-940. 10.1016/S0140-6736(03)14361-9, 14511925.
20. Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys 2007, 68:654-661. 10.1016/j.ijrobp.2007.03.010, 17467926.
21. Koukourakis M, Hlouverakis G, Kosma L, Skarlatos J, Damilakis J, Giatromanolaki A, Yannakakis D. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 1996, 34:315-322. 10.1016/0360-3016(95)02102-7, 8567332.
22. Chen M, Jiang GL, Fu XL, Wang LJ, Qian H, Chen GY, Zhao S, Liu TF. The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer. Lung Cancer 2000, 28:11-19. 10.1016/S0169-5002(99)00113-0, 10704704.
23. Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, Hillman SL, Farr GH, Tazelaar HD, Krook JE, Geoffroy FJ, Salim M, Arusell RM, Mailliard JA, Schaefer PL, Jett JR. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 59:943-951. 10.1016/j.ijrobp.2004.01.055, 15234027.
24. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L, Hochstenbag M, Boersma L, Wouters B, Lammering G, Vansteenkiste J, Lambin P. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006, 24:1057-1063. 10.1200/JCO.2005.02.9793, 16505424.
25. Videtic GM, Fung K, Tomiak AT, Stitt LW, Dar AR, Truong PT, Yu EW, Vincent MD, Kocha WI. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer 2001, 33:249-258. 10.1016/S0169-5002(00)00240-3, 11551420.
26. Cisplatin, etoposide, and two different schedules of radiation therapy in treating patients with limited-stage small cell lung cancer. , http://clinicaltrials.gov/ct2/show/NCT00433563
27. Three different radiation therapy regimens in treating patients with limited-stage small cell lung cancer receiving cisplatin and etoposide. , http://www.clinicaltrials.gov/ct2/show/NCT00632853
28. Kepka L, Danilova V, Saghatelyan T, Bajcsay A, Utehina O, Stojanovic S, Yalman D, Demiral A, Bondaruk O, Kuddu M, Jeremic B, . International Atomic Energy Agency (IAEA) Resources and management strategies for the use of radiotherapy in the treatment of lung cancer in Central and Eastern European countries: results of an International Atomic Energy Agency (IAEA) survey. Lung Cancer 2007, 56:235-245. 10.1016/j.lungcan.2006.12.011, 17267070, International Atomic Energy Agency (IAEA).
29. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004, 22:4837-4845. 10.1200/JCO.2004.01.178, 15570087.
30. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 2006, 17:543-552. 10.1093/annonc/mdj094, 16344277.
31. Videtic GM, Truong PT, Dar AR, Yu EW, Stitt LW. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation. Int J Radiat Oncol Biol Phys 2003, 57:709-716. 10.1016/S0360-3016(03)00635-7, 14529775.
32. Videtic GM, Belderbos JS, Spring Kong FM, Kepka L, Martel MK, Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). Int J Radiat Oncol Biol Phys 2008, 72:327-334. 10.1016/j.ijrobp.2008.03.075, 18793952.
33. Roof KS, Fidias P, Lynch TJ, Choi NC. Radiation dose intensification in limited-stage small-cell lung cancer. Clin Lung Cancer 2003, 4:339-346. 10.3816/CLC.2003.n.013, 14599300.